Showing results (51-60 of 61) with videos related to

Sort By:
Pageof 7
Proceedings of the National Academy of Sciences of the United States of America|June 23, 2009
Microfabricated tissue gauges to measure and manipulate forces from 3D microtissuesWesley R Legant, Amit Pathak, Michael T Yang, et al.
Endoscopic Ultrasound|April 26, 2017
Endoscopic ultrasound of peritoneal spacesMalay Sharma, Jayan Gopinath Madambath, Piyush Somani, et al.
Cell Reports|December 4, 2025
Cadherin-1-mediated communication at the leader-follower boundary controls mouse breast tumor organoid collective migrationVasilios A Morikis, Diego Barra Avila, Alessandra DiMauro, et al.
Biophysical Journal|April 27, 2017
Increased Tissue Stiffness in Tumors from Mice with Neurofibromatosis-1 Optic GliomaChristopher Walter, Lindsey Crawford, Melinda Lai, et al.
ACS Omega|January 29, 2024
Understanding the Interaction Mechanism between the Epinephrine Neurotransmitter and Small Gold Nanoclusters (Au<sub></sub>; <i>n</i> = 6, 8, and 10): A Computational InsightNagendra Prasad Yadav, Tarun Yadav, Sangram Pattanaik, et al.
Biomaterials|May 4, 2020
Control of adhesive ligand density for modulation of nucleus pulposus cell phenotypeMarcos N Barcellona, Julie E Speer, Bailey V Fearing, et al.
Elife|May 31, 2019
DDR2 controls breast tumor stiffness and metastasis by regulating integrin mediated mechanotransduction in CAFsSamantha Vh Bayer, Whitney R Grither, Audrey Brenot, et al.
Developmental Cell|January 10, 2023
A Cdh3-β-catenin-laminin signaling axis in a subset of breast tumor leader cells control leader cell polarization and directional collective migrationPriscilla Y Hwang, Jairaj Mathur, Yanyang Cao, et al.
FASEB Journal : Official Publication of the Federation of American Societies for Experimental Biology|October 23, 2019
Mechanosensitive transcriptional coactivators MRTF-A and YAP/TAZ regulate nucleus pulposus cell phenotype through cell shapeBailey V Fearing, Liufang Jing, Marcos N Barcellona, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 10, 2007
A phase 1 escalating single-dose and weekly fixed-dose study of cetuximab: pharmacokinetic and pharmacodynamic rationale for dosingPaula M Fracasso, Howard Burris, Matthew A Arquette, et al.
Pageof 7